# Butterfly Network, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Butterfly Network, Inc.). ## Overview Butterfly Network, Inc. develops handheld ultrasound systems built around its proprietary Ultrasound-on-Chip semiconductor technology, which replaces traditional piezoelectric crystal-based designs. The company sells the Butterfly iQ3, iQ+, iQ+ Bladder, Butterfly Move, and veterinary probes together with software subscriptions, cloud tools, education products, and professional services. Its business is designed to make point-of-care imaging portable and easier to use across hospitals, clinics, emergency services, home care, and global health settings. Butterfly also has a growing embedded-technology and licensing element, where it supplies semiconductor chips and software support to partners. The company was founded in 2011 and now sells in more than 30 countries through direct sales, distributors, and eCommerce. ## Products & services • Butterfly iQ3 handheld ultrasound probe • Butterfly iQ+ and iQ+ Bladder devices • Butterfly Move and veterinary ultrasound devices • SaaS subscriptions, support, and cloud software • Butterfly Academy, Certified courses, and ScanLab app • Teleguidance and healthcare-system software tools • Butterfly Embedded chip and licensing partnerships - **Ultrasound devices** (65%) — Handheld ultrasound probes and related accessories used for point-of-care imaging in human and veterinary care. - **Software subscriptions and cloud services** (25%) — SaaS, support, teleguidance, and cloud-hosted workflow tools sold to healthcare customers. - **Education and training** (5%) — Butterfly Academy, Certified courses, and in-app educational content that help users adopt and use the devices. - **Butterfly Embedded and licensing** (5%) — Semiconductor chip deliveries, SDKs, and partnership support services tied to co-development and licensing. - Butterfly iQ3 handheld ultrasound probe - Butterfly iQ+ and iQ+ Bladder devices - Butterfly Move and veterinary ultrasound devices - SaaS subscriptions, support, and cloud software - Butterfly Academy, Certified courses, and ScanLab app - Teleguidance and healthcare-system software tools - Butterfly Embedded chip and licensing partnerships ## Customers Butterfly sells primarily to healthcare systems, physicians, and healthcare providers that want portable ultrasound at the point of care. In the U.S., the company focuses on large healthcare-system implementations through direct sales, while internationally it uses distributors and eCommerce where permitted. It also serves veterinarians through dedicated devices and channels, and it has a smaller but strategically important base of partners using Butterfly Embedded technology. Beyond commercial customers, Butterfly places devices with NGOs and global health organizations for low-resource settings and humanitarian use. The company is also expanding into home-care and at-risk care-management programs where imaging can help reduce readmissions and support chronic-disease monitoring. - **Hospital and health system enterprises** (primary) — Buy probes, software subscriptions, and deployment services to standardize point-of-care ultrasound across departments and clinicians. - **Individual physicians and clinicians** (primary) — Purchase devices through direct sales or eCommerce because the handheld form factor makes ultrasound accessible outside traditional imaging departments. - **Out-of-hospital care providers** (secondary) — Clinics, EMS, urgent care, and home-care teams buy portable imaging tools to support diagnosis and monitoring at the bedside or in the field. - **Veterinary customers** (secondary) — Buy Butterfly iQ+/iQ3 Vet devices for animal imaging and workflow support in veterinary practices. - **Global health and NGO partners** (emerging) — Use donated or deployed devices in underserved communities where access to imaging is limited. - **Embedded technology partners** (emerging) — License semiconductor chips and software support for co-development and integration into partner products. - Large hospital systems buying enterprise deployments and workflow software - Physicians and clinicians purchasing devices for point-of-care imaging - Emergency medicine, clinics, EMS, and home-care providers needing portability - Veterinarians buying dedicated vet probes and software - NGOs and global health partners using devices in low-resource settings - Healthcare organizations seeking readmission reduction and remote care tools ## Geography Butterfly is headquartered in Burlington, Massachusetts and operates through subsidiaries in the United States, Australia, Germany, the Netherlands, the United Kingdom, and Taiwan. The company sells in over 30 countries through direct sales, distributors, and eCommerce, and its commercial footprint extends to approximately 40 countries. It sells directly in Germany and the United Kingdom, while other markets are served through partners and online channels. Outside core commercial geographies, Butterfly devices are also used in more than 70 low-resource settings and over 100 countries through NGO and global health collaborations. Geography matters because regulatory clearance, channel structure, and local reimbursement or adoption patterns shape where the company can sell devices and software most effectively. - Headquartered in Burlington, Massachusetts, with global operating subsidiaries - Direct sales in Germany and the United Kingdom - Commercial footprint in approximately 40 countries - Products sold in over 30 countries through direct, distributor, and eCommerce channels - Devices used in over 100 countries through NGOs and global health partners - Low-resource settings are an important non-commercial deployment channel ## Strategy Butterfly’s strategy is to deepen penetration in core point-of-care ultrasound by expanding from individual users into hospital enterprises and academic institutions. It is also pushing beyond the hospital into clinics, EMS, home care, and chronic-care management, where portable imaging can support earlier intervention and lower-cost care. A key strategic pillar is Butterfly Embedded, which extends the company’s semiconductor platform into co-development and licensing opportunities and can broaden monetization beyond device sales. The company is also investing in education, partner training, and commercial execution to improve adoption and retention across its installed base. These priorities are meant to shift the business toward recurring software and services while preserving the device-led entry point. - **Enterprise hospital penetration** (short-term) — Large health systems can standardize usage across many clinicians and create durable device, software, and support demand. - **Out-of-hospital and home-care expansion** (medium-term) — Portable ultrasound can move imaging closer to the patient and support lower-cost care pathways outside traditional radiology settings. - **Butterfly Embedded monetization** (medium-term) — Licensing and co-development can extend the semiconductor platform into new revenue streams beyond probe sales. - **Education and workflow adoption** (short-term) — Training lowers the barrier to ultrasound use for clinicians without prior imaging expertise and supports repeat usage. - Expand deeper into hospital enterprises and academic institutions - Grow adoption in out-of-hospital settings such as clinics and EMS - Build home-care and chronic-care management use cases - Scale Butterfly Embedded co-development and licensing - Increase software and services mix over time - Invest in education and partner training to accelerate adoption ## Risks Butterfly remains exposed to the risk that adoption of handheld ultrasound grows more slowly than expected, especially because the company has a limited history of sustained profitability and continues to invest heavily in commercialization. Its products depend on software, cloud services, and third-party components, so cybersecurity incidents or supplier disruptions could impair manufacturing, customer use, or data security. Regulatory and reimbursement complexity also matters because the company sells medical devices across multiple jurisdictions and must maintain clearances such as FDA and CE approvals. Competitive pressure is significant because larger imaging and medtech companies can bundle ultrasound into broader hospital relationships, while Butterfly must prove that its portable model delivers clinical and economic value. The business also faces execution risk in new channels such as home care, embedded licensing, and global health partnerships, where adoption, compliance, and support requirements can be uneven. - **Cybersecurity breach of products or IT systems** [high] — Devices connect to customer IT environments and cloud services, so a breach could disrupt care, expose PHI, and trigger recalls or litigation. - **Supplier disruption or third-party component failure** [high] — The company relies on external hardware and software inputs, and a supplier incident could affect production or product functionality. - **Continued operating losses and capital needs** [high] — Butterfly has a limited revenue base relative to its commercialization and R&D ambitions, so funding needs can remain elevated. - **Regulatory and market authorization risk** [medium] — Medical device sales depend on maintaining FDA, CE, and other approvals in each market. - **Adoption and reimbursement uncertainty** [medium] — The value proposition depends on clinicians changing workflows and payors or providers recognizing cost savings. - Slow adoption of handheld ultrasound could limit growth and prolong losses - Cybersecurity breaches could disrupt devices, cloud tools, or patient data - Third-party component or software failures could interrupt manufacturing or service - Regulatory clearance and compliance risk across multiple countries - Competitive pressure from larger medtech and imaging vendors - Execution risk in home care, embedded licensing, and NGO channels ## Accounting Butterfly recognizes product revenue at a point in time when control transfers, while SaaS subscriptions, support, and term-based SDKs are recognized ratably over time, so the mix of device sales versus software materially affects quarterly revenue timing. The company also sells multi-element contracts that can include hardware, software subscriptions, and services, which requires allocation of transaction price across performance obligations. Quarterly results can be volatile because device shipments and partner chip deliveries may shift revenue between periods, and management explicitly notes that the revenue mix can change with the timing of device sales. Cost of revenue is also sensitive to product mix, launch timing, and manufacturing scale, which can create margin swings as newer probes ramp. Because the company operates with significant estimates and judgments, investors should watch for revenue deferrals, contract allocation, and the treatment of licensing and partnership support arrangements. - **Revenue recognition for bundled device and software contracts** — Revenue timing and deferred revenue balances - **Point-in-time versus over-time recognition** — Quarterly comparability and revenue mix - **Quarterly volatility from device sales timing** — Reported growth rates and margin trends - **Estimates and judgments in contract allocation** — Revenue deferral and recognized margin - Point-in-time revenue for devices and perpetual SDKs affects shipment timing - Over-time recognition for SaaS, support, and term-based SDKs smooths revenue - Multi-element contracts require allocation across hardware, software, and services - Quarterly revenue can swing with probe shipments and partner chip deliveries - Product mix affects cost of revenue and gross margin - Licensing and partnership support revenue may depend on contract terms and milestones --- *Last updated: 2026-08-11T04:46:25.145960+00:00*